PCOS Explained: Diagnosis, Phenotypes, and the RRM Approach

What is PCOS?

Polycystic ovary syndrome is a heterogeneous endocrine and metabolic condition characterised by some combination of irregular ovulation, androgen excess, and polycystic ovarian morphology on ultrasound, with consequences that extend well beyond the menstrual cycle.

PCOS affects between roughly 6 and 15 percent of reproductive-age women, depending on which diagnostic criteria are applied and which population is studied, per the Deswal 2021 systematic review. It is the most common endocrine disorder in women of reproductive age and a leading cause of anovulatory infertility, hirsutism, acne, and irregular menses, per Solomon's foundational epidemiology review. Prevalence is rising in several populations, with a large Chinese study documenting a substantial increase over the past decade.

The condition is best understood as a syndrome, not a disease. A diagnosis of PCOS captures a recognisable clinical pattern produced by what may be several distinct underlying biologies. Legro and Strauss 2002 mapped the molecular heterogeneity, and Singh et al. 2023 review the developmental, genetic, and epigenetic contributions now recognised in the etiology literature. Joshi 2024 argues that without stratification, future precision treatment is impossible.

The framing matters because it determines what gets investigated, what gets treated, and what gets followed across decades. Hunter and Sterrett made the point in 2000, in the American Family Physician journal, that PCOS is "not just infertility." A quarter-century later that observation remains the single most useful reframe a clinician can offer a patient newly given the label.

How PCOS is Diagnosed

Four diagnostic frameworks have shaped clinical practice over the past three decades. They differ in which features are required, how ultrasound morphology is weighted, and how prevalence is consequently measured.

The clinically dominant framework in most countries remains Rotterdam 2003, which is also the source of the four-phenotype classification used below. The 2019 ANZJOG extract of the international evidence-based guideline, authored by Costello and colleagues, restated Rotterdam and added explicit cautions for adolescent diagnosis. Bani Mohammad and Majdi Seghinsara review the place of anti-Mullerian hormone (AMH) in the diagnostic workup, a measurement the 2023 international guideline now permits in adults as an acceptable substitute for ultrasound morphology.

Two practical points follow. First, a Rotterdam-style diagnosis does not require polycystic ovaries on ultrasound and does not require irregular cycles in isolation. Second, three of the four frameworks treat hyperandrogenism (clinical or biochemical) as central, which makes a thorough androgen panel an essential part of the workup rather than an afterthought.

The Four PCOS Phenotypes

Rotterdam 2003 produced four phenotypes based on which combination of features a given patient meets. Each phenotype carries its own hormonal pattern and its own metabolic load, and the same diagnostic label can capture meaningfully different conditions, per Bil et al. 2016.

An RRM Phenotype Lens

Beyond the Rotterdam classification, RRM-trained clinicians often work with a complementary phenotype framework that names the dominant biological driver in a given patient. The categories are not mutually exclusive and a patient can carry features of more than one, but the lens guides workup and treatment.

This lens is operationally useful even where the literature has not yet validated it as a separate taxonomic system. It captures information a Rotterdam phenotype letter does not: which physiological process is most likely driving symptoms in the patient in front of you.

Why Standard Care Often Misses the Mark

The typical primary-care or general-gynaecology workflow for a newly suspected PCOS patient runs something like this: irregular cycles trigger a single transvaginal ultrasound, perhaps a fasting glucose and lipid panel, and a prescription for combined hormonal contraception. Acne and hirsutism are managed cosmetically. Anovulatory infertility, when it arrives, is referred onward to an IVF clinic.

Each step has a clinical logic in isolation. The cumulative pattern does not.

Combined hormonal contraception does not treat PCOS. It induces a withdrawal bleed that resembles a menstrual period, suppresses ovarian androgen production, and reduces visible symptoms. The cycle, the ovulation, and the underlying metabolic phenotype remain unaddressed underneath the suppression. Randomised data in PCOS show that both oral and vaginal combined formulations produce similar unfavourable metabolic effects, including changes in insulin sensitivity and lipid panels, per Mosorin and colleagues 2023. A separate cohort from the same Finnish group documented an association between former long-term combined contraceptive use and disordered glucose metabolism in perimenopause, per Mosorin et al. 2023.

Metformin, when added, is often dosed by guesswork rather than by phenotype assessment. Carpentier's 24-month study shows what sustained metformin can do in a PCOS cohort, including improvements in menses, hormones, and metabolic markers, but the literature also documents a growing role for myo-inositol as an alternative or adjunct with a milder side-effect profile, per Jamilian et al. 2017 and Fruzzetti et al. 2016.

The longer-term gap is more serious. Most women diagnosed with PCOS in their twenties are not actively followed for cardiometabolic risk, endometrial protection, or mental health into their forties and fifties, despite the documented elevation of risk in each domain, per Cooney and Dokras 2018 and Chandrasekaran and Sagili 2018. The condition is chronic, but the care pattern is acute.

The RRM Approach to PCOS

Restorative Reproductive Medicine treats PCOS as a chronic condition with distinct phenotypes that warrant phenotype-matched workup, lifestyle and metabolic intervention before suppression, and longitudinal follow-up across decades rather than across visits.

RRM-trained clinicians, including those working within the NaProTechnology and FEMM traditions, typically structure PCOS care around several core principles.

1. Charting cycles to establish a real baseline

Before any treatment, the patient's actual cycle is mapped using a standardised charting method, often the Creighton Model FertilityCare System or the FEMM biomarker app paired with urinary LH testing. The chart documents what is actually happening across cycles, including unobserved ovulatory dysfunction patterns that a simple "irregular periods" history misses entirely. A documented PCOS case from Kicinska and colleagues 2023 illustrates how charting-anchored care identifies hormonal patterns that calendar-based protocols overlook.

2. Phenotype-matched workup

A complete workup typically includes a full androgen panel (total testosterone, free testosterone or sex hormone binding globulin, DHEA-S, 17-hydroxyprogesterone to exclude non-classical congenital adrenal hyperplasia), markers of insulin resistance (fasting insulin and glucose with HOMA-IR, or an oral glucose tolerance test with insulin levels), inflammatory markers, thyroid function, AMH, and prolactin. Bani Mohammad and Majdi Seghinsara 2017 reviews the place of AMH. Joshi 2024 argues that workup of this depth is the precondition for any precision-treatment strategy.

3. Lifestyle and metabolic intervention before suppression

Dietary pattern, resistance training, sleep, and stress regulation are not soft adjuncts but the foundation of PCOS care, particularly for the insulin-resistant phenotype that dominates most clinic populations. The international guideline, summarised by Cowan and colleagues 2023, places lifestyle modification as first-line. Insulin-sensitising agents have a strong evidence base where appropriate, with myo-inositol and metformin both supported by randomised data. Greff et al. 2023 is the current meta-analysis of choice for inositol; DiNicolantonio and O'Keefe 2022 review the mechanism and the wider metabolic indications.

4. Ovulation restoration, not bleed simulation

For women seeking pregnancy, ovulation-induction agents (most commonly letrozole as first-line per the international guideline, with metformin as an adjunct in selected cases) are used in combination with charting and lab confirmation of ovulation. For women not currently seeking pregnancy, the goal is still to support a real ovulatory cycle where possible, because ovulation produces the progesterone that protects the endometrium and contributes to bone, cardiovascular, and mental health.

5. Longitudinal follow-up

PCOS care does not end when symptoms settle or a pregnancy succeeds. The same cardiometabolic, endometrial, and mental-health risks persist into perimenopause and beyond, per Torchen 2017. A serious PCOS care plan budgets for screening across decades, not visits.

PCOS and Fertility

PCOS is the most common cause of anovulatory infertility, and it is also one of the most treatable. Live-birth rates with first-line medical management compare favourably to many other infertility diagnoses.

The international evidence-based guideline, extracted in the 2019 Costello ANZJOG paper, recommends letrozole as the first-line pharmacological agent for anovulatory infertility in PCOS. Letrozole, an aromatase inhibitor, was first applied to ovulation induction in this population by Mitwally and Casper in 2001. Sawant and Bhide 2019 survey the wider treatment landscape, including clomiphene citrate, gonadotropins, ovarian drilling, and IVF for resistant cases. A 2022 randomised controlled trial by Dai and colleagues documents outcomes for sequential letrozole-gonadotrophin combinations in PCOS.

For the insulin-resistant phenotype, weight optimisation and insulin sensitisation are not optional. Singh and colleagues 2023 review the management landscape including future therapeutics; Regidor and Schindler 2016 documents the German observational experience with myo-inositol in infertile PCOS women.

RRM-trained clinicians typically combine these pharmacological tools with charting-based timing, which improves the precision of intercourse timing during induction cycles and provides objective confirmation that ovulation actually occurred. The result, in clinical experience, is that many women with PCOS achieve pregnancy without ever needing IVF, even after prior failed cycles elsewhere. When IVF is required, the underlying metabolic and ovulatory dysfunction still warrants treatment, because pregnancy and long-term health both improve when the condition is addressed rather than bypassed.

PCOS and Long-Term Health

PCOS is not a fertility-window condition. The hormonal and metabolic features that define the syndrome persist throughout adult life and translate into elevated risk across several domains.

Cardiometabolic risk

Women with PCOS have higher rates of metabolic syndrome, insulin resistance, type 2 diabetes, and cardiovascular disease, particularly in the hyperandrogenic phenotypes A and B, per Torchen 2017, Bil et al. 2016, and Chandrasekaran and Sagili 2018. A descriptive cross-sectional study by Giri and colleagues 2022 in Nepal documents a high prevalence of metabolic syndrome in tertiary-care PCOS populations. Routine screening for glycemia and lipids, repeated at intervals that match individual risk, is standard in serious PCOS care.

Endometrial protection

Chronic anovulation produces chronic unopposed estrogen exposure of the endometrium, which raises the risk of endometrial hyperplasia and, over time, endometrial cancer. Ovulation, by producing luteal-phase progesterone, is the body's own endometrial protective mechanism. This is part of why "restoring ovulation" matters clinically even outside the context of pregnancy.

Mental health

Women with PCOS are more likely to experience anxiety, depression, and disordered eating, per Chaudhari et al. 2018 and Krug et al. 2019. Farrell and Antoni 2010 map the biobehavioural mechanisms linking insulin resistance, inflammation, and depression. A population-based study of postpartum depression in PCOS by Koric and colleagues 2021, with a follow-up Hispanic/non-Hispanic comparison by Fugal and colleagues 2022, documents elevated postpartum depressive symptoms specifically in this group. Mental health screening belongs in the routine PCOS visit, not as an afterthought.

Bone health

Bone health is also affected. A meta-analysis and endocrine-context review of bone density and fracture prevalence in PCOS documents an underappreciated risk signal that warrants attention as women with PCOS age into the perimenopausal transition.

The cumulative picture is that PCOS is a multi-system condition with implications that compound across decades, and that long-term follow-up is a feature of good care, not a luxury, per Cooney and Dokras 2018.

Adolescent PCOS

Diagnosing PCOS in adolescence is more complex than in adulthood, because the normal physiology of the first few years after menarche includes cycle irregularity, anovulatory cycles, and physiological hyperandrogenism that resolve as the hypothalamic-pituitary-ovarian axis matures. Applying adult Rotterdam criteria too early risks over-diagnosis and the start of long-term suppressive therapy for a pattern that would have resolved on its own.

The international evidence-based guideline explicitly cautions against this. Bremer 2010 reviewed the pediatric considerations in detail. Williams, Mortada, and Porter 2016 in the American Family Physician journal summarises the diagnostic threshold in a way suited to primary-care practice. A key reframe for adolescents and their families is the American Academy of Pediatrics committee opinion by Diaz, Laufer, and Breech (2006), which establishes the menstrual cycle itself as a vital sign worth tracking with the same seriousness as growth and blood pressure.

In practice, this means an adolescent with irregular cycles, hirsutism, or acne benefits from charting, careful workup, and time, before a definitive PCOS label and a long-acting hormonal prescription. Where features clearly persist beyond two to three years post-menarche and meet adult criteria, formal diagnosis follows. Where they do not, watchful charting plus targeted lifestyle and metabolic support is often the appropriate path.

PCOS and Co-occurring Conditions

PCOS rarely arrives alone. The conditions that cluster with it carry implications for both workup and treatment plan.

Endometriosis. Co-occurrence of PCOS and endometriosis is real and meaningful, per Schliep and colleagues 2023. Women presenting with infertility, pelvic pain, or dyspareunia in addition to PCOS features warrant evaluation for endometriosis as well, and the surgical and medical paths differ enough that getting both diagnoses right changes the plan substantially.

Thyroid disorders. Hypothyroidism and Hashimoto's autoimmune thyroiditis are over-represented in women with PCOS. Thyroid function should be checked at diagnosis and rechecked if symptoms shift.

Eating disorders and disordered eating. Binge-eating disorder is particularly over-represented, per Krug et al. 2019. Restrictive eating and orthorexia also appear, sometimes triggered or sustained by well-intentioned weight-loss advice. A trauma-informed approach to lifestyle counselling, with a referral to a clinician trained in eating disorders when indicated, is part of safe care.

Non-classical congenital adrenal hyperplasia (NCCAH). A 17-hydroxyprogesterone draw early in the follicular phase is part of any complete PCOS workup, because NCCAH can present with an identical clinical picture and is managed differently.

Obstructive sleep apnoea. Sleep apnoea is more common in PCOS than in age- and BMI-matched controls and contributes independently to insulin resistance and cardiovascular risk. Sleep history belongs in the initial visit.

Postpartum depression. The postpartum window is a particularly vulnerable one for women with PCOS, per Koric 2021. Proactive screening and warm handoffs to postpartum mental health resources are protective.

Frequently Asked Questions

See the PCOS glossary definition for clinical terminology, and read the FAQ on letrozole as first-line treatment for a detailed evidence summary.